L-Dopa Treatment and Parkinson's Disease
Identifieur interne : 002950 ( Main/Exploration ); précédent : 002949; suivant : 002951L-Dopa Treatment and Parkinson's Disease
Auteurs : Andrew Lees (neurologue) [Royaume-Uni]Source :
- QJM: An International Journal of Medicine [ 1460-2725 ] ; 1986-06.
Abstract
Seventeen years after its introduction, L-dopa, now administered in combination with a peripheral dopa decarboxylase inhibitor remains the most effective palliative remedy for Lewy body Parkinson's disease. A therapeutic effect to large doses is so consistent that alternative diagnoses should be considered in any patient with a Parkinsonian syndrome who fails completely to respond. Despite improving the quality of life, it probably does not influence appreciably the reduced life expectancy in Parkinson's disease and the long-term therapeutic response is frequently marred by drug-induced oscillations in motor performance, dyskinesias and psychotoxicity. Experimental studies using continuous intravenous infusions of L-dopa in order to obtain constant plasma levels suggests that additional refinements in management may be achieved by the design of a practical controlled delivery system, and prototype pumps and sustained release formulations are already under evaluation.
Url:
DOI: 10.1093/oxfordjournals.qjmed.a067981
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>L-Dopa Treatment and Parkinson's Disease</title><author wicri:is="90%"><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name><affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A40B79A7A11AB14C82CF006B286F515A5B8256C6</idno><date when="1986" year="1986">1986</date><idno type="doi">10.1093/oxfordjournals.qjmed.a067981</idno><idno type="url">https://api.istex.fr/document/A40B79A7A11AB14C82CF006B286F515A5B8256C6/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001A18</idno><idno type="wicri:Area/Main/Curation">001763</idno><idno type="wicri:Area/Main/Exploration">002950</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">L-Dopa Treatment and Parkinson's Disease</title><author wicri:is="90%"><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name><affiliation><wicri:noCountry code="subField">London WC1</wicri:noCountry><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">QJM: An International Journal of Medicine</title><idno type="ISSN">1460-2725</idno><idno type="eISSN">1460-2393</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1986-06">1986-06</date><biblScope unit="volume">59</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="535">535</biblScope><biblScope unit="page" to="547">547</biblScope></imprint><idno type="ISSN">1460-2725</idno></series><idno type="istex">A40B79A7A11AB14C82CF006B286F515A5B8256C6</idno><idno type="DOI">10.1093/oxfordjournals.qjmed.a067981</idno><idno type="ArticleID">59.3.535</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1460-2725</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Seventeen years after its introduction, L-dopa, now administered in combination with a peripheral dopa decarboxylase inhibitor remains the most effective palliative remedy for Lewy body Parkinson's disease. A therapeutic effect to large doses is so consistent that alternative diagnoses should be considered in any patient with a Parkinsonian syndrome who fails completely to respond. Despite improving the quality of life, it probably does not influence appreciably the reduced life expectancy in Parkinson's disease and the long-term therapeutic response is frequently marred by drug-induced oscillations in motor performance, dyskinesias and psychotoxicity. Experimental studies using continuous intravenous infusions of L-dopa in order to obtain constant plasma levels suggests that additional refinements in management may be achieved by the design of a practical controlled delivery system, and prototype pumps and sustained release formulations are already under evaluation.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement><orgName><li>National Hospital for Neurology and Neurosurgery</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002950 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002950 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A40B79A7A11AB14C82CF006B286F515A5B8256C6
|texte= L-Dopa Treatment and Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |